vs
ARTIVION, INC.（AORT）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是ARTIVION, INC.的1.3倍（$151.1M vs $116.0M），ARTIVION, INC.同比增速更快（19.2% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs 5.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AORT vs RGR — 直观对比
营收规模更大
RGR
是对方的1.3倍
$116.0M
营收增速更快
AORT
高出15.6%
3.6%
自由现金流更多
RGR
多$20.3M
$-7.9M
两年增速更快
AORT
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $151.1M |
| 净利润 | $2.4M | — |
| 毛利率 | 63.1% | 17.8% |
| 营业利润率 | 9.2% | 2.3% |
| 净利率 | 2.1% | — |
| 营收同比 | 19.2% | 3.6% |
| 净利润同比 | 114.7% | — |
| 每股收益（稀释后） | $0.06 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRGR
| Q4 25 | $116.0M | $151.1M | ||
| Q3 25 | $113.4M | $126.8M | ||
| Q2 25 | $113.0M | $132.5M | ||
| Q1 25 | $99.0M | $135.7M | ||
| Q4 24 | $97.3M | $145.8M | ||
| Q3 24 | $95.8M | $122.3M | ||
| Q2 24 | $98.0M | $130.8M | ||
| Q1 24 | $97.4M | $136.8M |
净利润AORTRGR
| Q4 25 | $2.4M | — | ||
| Q3 25 | $6.5M | $1.6M | ||
| Q2 25 | $1.3M | $-17.2M | ||
| Q1 25 | $-505.0K | $7.8M | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-2.3M | $4.7M | ||
| Q2 24 | $-2.1M | $8.3M | ||
| Q1 24 | $7.5M | $7.1M |
毛利率AORTRGR
| Q4 25 | 63.1% | 17.8% | ||
| Q3 25 | 65.6% | 15.1% | ||
| Q2 25 | 64.7% | 3.9% | ||
| Q1 25 | 64.2% | 22.0% | ||
| Q4 24 | 63.2% | 22.8% | ||
| Q3 24 | 63.7% | 18.5% | ||
| Q2 24 | 64.6% | 22.3% | ||
| Q1 24 | 64.6% | 21.5% |
营业利润率AORTRGR
| Q4 25 | 9.2% | 2.3% | ||
| Q3 25 | 11.1% | -2.7% | ||
| Q2 25 | 7.4% | -15.6% | ||
| Q1 25 | 2.2% | 6.2% | ||
| Q4 24 | 2.7% | 7.8% | ||
| Q3 24 | 4.6% | 3.1% | ||
| Q2 24 | 6.6% | 6.9% | ||
| Q1 24 | 26.0% | 5.5% |
净利率AORTRGR
| Q4 25 | 2.1% | — | ||
| Q3 25 | 5.7% | 1.2% | ||
| Q2 25 | 1.2% | -13.0% | ||
| Q1 25 | -0.5% | 5.7% | ||
| Q4 24 | -16.9% | — | ||
| Q3 24 | -2.4% | 3.9% | ||
| Q2 24 | -2.2% | 6.3% | ||
| Q1 24 | 7.7% | 5.2% |
每股收益（稀释后）AORTRGR
| Q4 25 | $0.06 | $0.22 | ||
| Q3 25 | $0.13 | $0.10 | ||
| Q2 25 | $0.03 | $-1.05 | ||
| Q1 25 | $-0.01 | $0.46 | ||
| Q4 24 | $-0.40 | $0.62 | ||
| Q3 24 | $-0.05 | $0.28 | ||
| Q2 24 | $-0.05 | $0.47 | ||
| Q1 24 | $0.18 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $92.5M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $283.8M |
| 总资产 | $884.8M | $342.0M |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTRGR
| Q4 25 | $64.9M | $92.5M | ||
| Q3 25 | $73.4M | $80.8M | ||
| Q2 25 | $53.5M | $101.4M | ||
| Q1 25 | $37.7M | $108.3M | ||
| Q4 24 | $53.5M | $105.5M | ||
| Q3 24 | $56.2M | $96.0M | ||
| Q2 24 | $55.0M | $105.6M | ||
| Q1 24 | $51.1M | $115.3M |
总债务AORTRGR
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRGR
| Q4 25 | $448.2M | $283.8M | ||
| Q3 25 | $438.7M | $279.6M | ||
| Q2 25 | $419.9M | $289.3M | ||
| Q1 25 | $294.3M | $321.5M | ||
| Q4 24 | $276.2M | $319.6M | ||
| Q3 24 | $304.7M | $314.9M | ||
| Q2 24 | $295.1M | $321.5M | ||
| Q1 24 | $295.0M | $332.0M |
总资产AORTRGR
| Q4 25 | $884.8M | $342.0M | ||
| Q3 25 | $857.7M | $342.3M | ||
| Q2 25 | $838.4M | $349.5M | ||
| Q1 25 | $791.2M | $379.0M | ||
| Q4 24 | $789.1M | $384.0M | ||
| Q3 24 | $803.1M | $373.5M | ||
| Q2 24 | $789.5M | $376.7M | ||
| Q1 24 | $784.0M | $385.0M |
负债/权益比AORTRGR
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $12.3M |
| 自由现金流率自由现金流/营收 | -6.9% | 8.2% |
| 资本支出强度资本支出/营收 | 23.7% | 2.1% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $38.5M |
8季度趋势，按日历期对齐
经营现金流AORTRGR
| Q4 25 | $19.6M | $15.5M | ||
| Q3 25 | $22.3M | $12.9M | ||
| Q2 25 | $15.0M | $14.7M | ||
| Q1 25 | $-17.0M | $11.1M | ||
| Q4 24 | $10.1M | $20.0M | ||
| Q3 24 | $11.5M | $9.4M | ||
| Q2 24 | $6.1M | $18.7M | ||
| Q1 24 | $-5.5M | $7.3M |
自由现金流AORTRGR
| Q4 25 | $-7.9M | $12.3M | ||
| Q3 25 | $17.7M | $7.0M | ||
| Q2 25 | $11.7M | $9.1M | ||
| Q1 25 | $-20.6M | $10.0M | ||
| Q4 24 | $8.7M | $16.4M | ||
| Q3 24 | $7.8M | $2.6M | ||
| Q2 24 | $3.6M | $10.1M | ||
| Q1 24 | $-9.1M | $5.6M |
自由现金流率AORTRGR
| Q4 25 | -6.9% | 8.2% | ||
| Q3 25 | 15.6% | 5.5% | ||
| Q2 25 | 10.4% | 6.9% | ||
| Q1 25 | -20.8% | 7.4% | ||
| Q4 24 | 9.0% | 11.2% | ||
| Q3 24 | 8.2% | 2.1% | ||
| Q2 24 | 3.7% | 7.7% | ||
| Q1 24 | -9.3% | 4.1% |
资本支出强度AORTRGR
| Q4 25 | 23.7% | 2.1% | ||
| Q3 25 | 4.1% | 4.6% | ||
| Q2 25 | 2.9% | 4.2% | ||
| Q1 25 | 3.7% | 0.8% | ||
| Q4 24 | 1.5% | 2.5% | ||
| Q3 24 | 3.8% | 5.5% | ||
| Q2 24 | 2.6% | 6.6% | ||
| Q1 24 | 3.7% | 1.3% |
现金转化率AORTRGR
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | 8.15× | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | -0.73× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
